<DOC>
	<DOCNO>NCT01860222</DOCNO>
	<brief_summary>The aim study compare operative complication short-/long-term therapeutic effect percutaneous local ablative therapy ( PLAT ) versus surgical resection ( SR ) small hepatocellular carcinoma ( HCC ) patient clinically significant portal hypertension ( CSPH ) lend clinical theoretical basis therapeutic scheme disease .</brief_summary>
	<brief_title>Surgical Resection Versus Percutaneous Local Ablative Therapy Hepatocellular Carcinoma</brief_title>
	<detailed_description>HCC major health problem worldwide , estimate incidence range 500,000 1,000,000 new case annually . It fifth common cancer world third common cause cancer-related death , especially East-Asia countries.SR remain first therapeutic option cure suitable 9 % —27 % patients.The presence significant background cirrhosis often preclude liver resection HCC.Even though HCC patient undergo SR，the incidence posthepatectomy liver failure ( PHLF ) death would high，especially HCC patient complicate CSPH，whose correspond risk PHLF persistent PHLF 59.02 % 14.75 % respectively past study . It extremely urgent search safe effective mean subgroup HCC patients.PLAT , recently develop local ablative technique , attract great interest popularity effectiveness safety , 3-year survival rate 62-77 % , low treatment complication rate 8-9 % low treatment mortality rate 0-0.5 % .However , still debate whether PLAT SR suitable therapy HCC.To knowledge , study therapy HCC complicate CSPH .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . 18 Years ＜ ge ≤ 70 Y , KPS ≥ 70 2 . A solitary HCC ≤ 5cm diameter , multiple HCC ( ≤3 ) , ≤3cm diameter without evidence radiologically definable vascular invasion extrahepatic metastasis . allow SR PLAT 3 . ChildPugh class A B , without history encephalopathy , ascites refractory diuretic , variceal bleed 4 . NO previous treatment HCC 5 . Platelet count＞40,000/mm3；prothrombin time prolongation 3 second 6 . Patients understand trial sign information consent 1. metastatic liver cancer 2 . Patients apparent cardiac , pulmonary , cerebral renal dysfunction , may affect treatment HCC 3 ) Patients disease may affect treatment mention 4） Patients participate clinical trial 5） Patients medical history malignant tumor 6 ) Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>CSPH</keyword>
	<keyword>Hepatectomy</keyword>
	<keyword>percutaneous local ablative</keyword>
	<keyword>therapy ( PLAT )</keyword>
	<keyword>randomize control trial ( RCTs )</keyword>
</DOC>